Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Non-Current Assets (2021 - 2025)

Kezar Life Sciences' Non-Current Assets history spans 4 years, with the latest figure at $7.7 million for Q3 2024.

  • For Q3 2024, Non-Current Assets fell 59.03% year-over-year to $7.7 million; the TTM value through Sep 2024 reached $47.8 million, down 33.11%, while the annual FY2023 figure was $14.3 million, 3.17% up from the prior year.
  • Non-Current Assets for Q3 2024 was $7.7 million at Kezar Life Sciences, down from $12.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $19.9 million in Q2 2023 and bottomed at $5.8 million in Q3 2022.
  • The 4-year median for Non-Current Assets is $7.7 million (2024), against an average of $10.8 million.
  • The largest annual shift saw Non-Current Assets surged 222.78% in 2023 before it tumbled 59.03% in 2024.
  • A 4-year view of Non-Current Assets shows it stood at $6.3 million in 2021, then soared by 120.51% to $13.8 million in 2022, then rose by 3.17% to $14.3 million in 2023, then tumbled by 46.05% to $7.7 million in 2024.
  • Per Business Quant, the three most recent readings for KZR's Non-Current Assets are $7.7 million (Q3 2024), $12.3 million (Q2 2024), and $13.5 million (Q1 2024).